A refractory duodenal ulcer with a biliary-duodenal fistula following the administration of bevacizumab.
Nihon Shokakibyo Gakkai Zasshi
; 113(7): 1244-50, 2016 07.
Article
in Ja
| MEDLINE
| ID: mdl-27383109
ABSTRACT
A 65-year-old woman with recurrent breast cancer was repeatedly treated with bevacizumab, an anti-VEGF antibody. In addition, she was also frequently prescribed a nonsteroidal anti-inflammatory drug for abdominal pain. Melena was revealed 2 months after the final treatment with bevacizumab, and an endoscopic study revealed a duodenal ulcer (DU) that was resistant to anti-ulcer therapy. A cholangiography identified a biliary-duodenal fistula with bile juice leaking from the ulcer base. Therefore, a biliary stent was placed into the common bile duct for 3 months until the DU healed. This is the first case of a refractory DU with a biliary-duodenal fistula in a patient treated with bevacizumab.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biliary Fistula
/
Angiogenesis Inhibitors
/
Duodenal Ulcer
/
Bevacizumab
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
Language:
Ja
Journal:
Nihon Shokakibyo Gakkai Zasshi
Year:
2016
Document type:
Article